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Abstract
The serine protease inhibitor protein C inhibitor (PCI) is expressed in many human tissues and exhibits broad protease
reactivity. PCI binds glycosaminoglycans and certain phospholipids, which modulate its inhibitory activity. Enteropeptidase
(EP) is a type II transmembrane serine protease mainly found on the brush border membrane of epithelial cells in the
duodenum, where it activates trypsinogen to initiate the digestion of food proteins. Some active EP is also present in
duodenal fluid and has been made responsible for causing pancreatitis in case of duodeno-pancreatic reflux. Together with
its substrate trypsinogen, EP is furthermore present in the epidermis and in some cancer cells. In this report, we show that
PCI inhibited EP with an apparent 2nd order rate constant of 4.48610
4 M
21 s
21. Low molecular weight (LMWH) and
unfractionated heparin (UFH) slightly reduced the inhibitory effect of PCI. The SI (stoichiometry of inhibition) value for the
inhibition of EP by PCI was 10.8 in the absence and 17.9 in the presence of UFH (10 U/ml). By inhibiting trypsin,
chymotrypsin, and additionally EP, PCI might play a role in the protection of the pancreas from autodigestion. Furthermore
the interaction of PCI with EP may influence the regulation of epithelial differentiation.
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Introduction
Protein C inhibitor (PCI) is a serine protease inhibitor and
a member of the serpin superfamily (serpinA5). PCI has originally
been described as a plasma inhibitor of activated protein C (APC)
[1,2]. Later, the inhibition of several other proteases, including the
pancreatic enzymes trypsin and chymotrypsin, by PCI has been
shown. [3–12]. Like other members of the serpin family, PCI acts
as a suicide substrate for its target proteases. Serpins have an
exposed reactive center loop (RCL) which offers a potential
cleavage site for the protease. The protease recognizes this
sequence and binds to the serpin, forming a reversible Michae-
lis-like complex. Then the protease cleaves the reactive site peptide
bond and the serpin incorporates the RCL into b-sheet A,
producing a covalent serpin-protease complex [13]. The enzyme-
inhibitor complex can dissociate, leaving behind an active protease
and a cleaved, inactive serpin.
Heparin and other glycosaminoglycans can modify the activity
and target enzyme specificity of PCI. The heparin-binding site is
a basic patch on helix H, which lies close to the reactive center
loop [14,15]. Heparin changes the charge of this area, thereby
modifying the affinity of PCI towards different proteases. Heparin
stimulates the inhibition of APC and thrombin [16], but abolishes
the inhibition of tissue kallikrein by PCI [6,17]. Antithrombin
(AT), another heparin-binding serpin, uses a different mechanism.
Both low molecular weight (LMWH) and unfractionated heparin
(UFH) bind to helix D. This binding leads to a conformational
change of AT and an additional part of the reactive center loop is
exposed. This results in increased inhibition of coagulation
proteases. UFH is furthermore big enough to span from helix D
to the protease. It thereby forms a template for AT and thrombin
and enhances their interaction [18].
By Northern blotting, a wide tissue distribution of PCI has been
demonstrated in humans. PCI mRNA is present in the liver,
kidney, heart, brain, lung, spleen, reproductive system and
pancreas [19,20]. Radtke et al. showed by in situ hybridization
that PCI is expressed in the exocrine part of the pancreas, and by
Western blotting that the protein is present in pancreatic fluid
[21]. We have shown that PCI mRNA and protein are also
present in keratinocytes of the human skin [22]. Its expression is
increased in the more differentiated layers of the epidermis [23].
PCI is also present in several body fluids and secretions, e.g. in
plasma (,100 nM) and seminal fluid (,4 mM) [24]. In rodents,
PCI is almost exclusively present in the reproductive tract [19].
This makes it difficult to study the effect of PCI outside the
reproductive tract in animal models. Because of its wide tissue
distribution, PCI may have several functions in humans. So far,
very little is known about these functions. PCI might have
a protective effect against cancer progression [25–29].
Since PCI has affinity for glycosaminoglycans and phospholi-
pids, both components of the cell membrane, cell membrane
association of PCI is not unlikely. We were therefore interested in
analyzing the interaction of PCI with serine proteases also present
in or on cell membranes. So far there are only a few indications in
the literature, suggesting that PCI interacts with type II trans-
membrane serine proteases [30,31]. However, as far as inhibition
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concerned, no data is available on these interactions. It was
therefore the aim of this study to analyze the interaction of PCI
with enteropeptidase (EP; other names: enterokinase, PRSS7,
TMPRSS15). EP (EC 3.4.21.9) is a type II transmembrane serine
protease, located mainly at the brush border membrane of the
epithelial cells of the duodenum and jejunum [32]. Active EP also
occurs in duodenal fluid [33]. In the small intestine, EP activates
trypsinogen to trypsin [33]. Active human EP is composed of
a light and a heavy chain linked by a disulfide bond [33]. The
catalytic center is located on the light chain, whereas the heavy
chain is responsible for substrate specificity [34].
Activation of trypsinogen is an obligatory step in the pathogen-
esis of acute necrotizing pancreatitis [35]. So far, it is not fully
understood how trypsinogen is activated prematurely in vivo. This
function might be executed intracellularly by cathepsin B [36].
Some authors also suggest a role of EP by reflux of duodenal fluid
into the pancreatic duct [37]. However, this theory remains
controversial. Outside the digestive system, EP and its substrate
trypsinogen are present in keratinocytes during their terminal
differentiation and might be involved in the regulation of
desquamation [38]. They are also expressed by oral squamous
cell carcinoma (HSC-3) and prostate cancer (PC-3) cell lines
[39,40]. Active trypsin can increase tumor cell invasiveness
[41,42]. Regulation of EP by protease inhibitors may therefore
be not only important in the digestive system, but also in
epidermal differentiation and tumor invasion.
We analyzed the interaction of EP with serpin-type protease
inhibitors (PCI, a1-antitrypsin (A1AT) and AT) and can show that
PCI is a strong inhibitor of EP with an apparent 2
nd order constant
(kapp) comparable to other PCI-protease interactions.
Results
Interaction of Human EP with PCI Leads to
Complex Formation
The interaction between recombinant human PCI and EP was
analyzed by SDS-PAGE followed by Western blotting using
antibodies to PCI and EP, respectively. Upon incubation of PCI
with EP, an increase in the intensity of the band corresponding to
the cleaved form of PCI and complex formation was seen
(Figure 1A). Under reducing conditions, the complex had
a molecular mass of about 95 kDa. This suggests an interaction
of PCI (46 kDa) with the light chain of EP (,50 kDa), on which
the serine protease domain is localized. To confirm this finding, we
used an antibody to the light chain of EP. We could observe
complex formation comparable to the results when anti-PCI IgG
was used (Figure 1B). We performed the same experiment under
non-reducing conditions, using an antibody to the heavy chain of
EP. Here, it was possible to see complex formation at about
215 kDa (Figure 1C).
Effect of Cofactors on the Inhibition of EP by PCI
In the EP activity assay, PCI strongly inhibited the amidolytic
activity of EP (Figure 2). UFH (Figure 2A) and LMWH (Figure 2B)
slightly reduced the inhibitory effect of PCI. Inhibition of EP with
purified plasma PCI showed similar results as with recombinant
PCI (data not shown). The phospholipid PAPS (1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phospho-L-serine) had no effect on the
inhibition of EP by PCI. Consistent with previous results [43],
PAPS strongly increased the inhibition of activated protein C in
a parallel experiment. Recombinant mouse PCI showed a similar
inhibitory effect on human EP as human PCI. With mouse PCI,
the inhibitory effect was also slightly reduced in the presence of
LMWH (data not shown).
The apparent 2
nd order rate constants (kapp) for the inhibition
of EP by human recombinant PCI were calculated under pseudo
1
st order conditions as outlined in Materials and Methods
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21 (mean 6 S.D., n=3). The SI value for
the inhibition of EP by PCI was 10.860.7 (mean 6 S.D., n=3).
In the presence of 10 U/ml UFH, it increased to 17.960.6
(mean 6 S.D., n=3) (Figure 4). The kapp values were corrected
for SIs by multiplication (kapp 6 SI), as this provides a measure
for the overall rate of association [13,44]. Corrected rate
constants (kapp 6 SI) were 4.84610
5 M
21 s
21 in the absence
Figure 1. PCI forms complexes with EP and is cleaved by EP.
Recombinant human PCI (440 nM) and EP (60 nM) were incubated at
37uC in a volume of 10 ml TCNB buffer for the time periods indicated.
Thereafter, an equal amount of Laemmli buffer with (A, B) or without
(C) 10% 2-mercaptoethanol was added. For time point zero, the
reagents were applied directly into Laemmli buffer. SDS-PAGE and
Western blotting were performed as described in Materials and
Methods using either monoclonal mouse anti-PCI IgG (A), rabbit anti-
EP (light chain) IgG (B) or mouse anti-EP (heavy chain) IgG (C),
respectively. The position of the molecular mass markers (kDa) is
indicated on the left. For control purposes, the left 2 lanes contained
PCI alone or EP alone, respectively.
doi:10.1371/journal.pone.0039262.g001
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5 M
21 s
21 in the presence of 10 U/ml UFH,
respectively.
Human PCI Forms Complexes with EP from
Natural Sources
In addition to recombinant human EP, the interaction of PCI
with two additional EPs from natural sources has been studied. EP
purified from porcine intestine (data not shown) as well as bovine
EP (bEP) purified from calf intestine formed complexes with PCI,
as demonstrated by SDS-PAGE analysis followed by Western
blotting (Figure 5). Functional assays showed strong inhibition of
bEP by PCI. The presence of PAPS did not affect the inhibitory
property of PCI towards bEP (Figure 6A), which is consistent with
results obtained with human EP.
A dose-response curve for the effect of UFH on the inhibition of
bEP by PCI was determined. Increasing concentrations of UFH
strongly reduced the inhibitory activity of PCI towards bEP
(Figure 6B). The interfering effect of UFH on bEP inhibition by
PCI was even stronger as compared with the inhibition of human
recombinant EP.
Interaction of Other Serpins with Human EP
To investigate if other serpins also interact with EP, activity
assays were performed in the presence of either A1AT or AT.
After incubation of EP with A1AT for 60 min, no significant
reduction of EP activity was observed, even at a molar
[A1AT]:[EP] ratio of 1000:1 (not shown). When EP was incubated
with AT for the same time, there was no reduction in EP activity.
However, AT slightly inhibited EP when either UFH or LMWH
were present (Figure 7). Heparin alone had no effect on the activity
of EP. Inhibitory activity of A1AT and AT was assured by
Figure 2. Inhibition of EP by PCI in the absence or presence of
heparin. EP (0.3 nM) was incubated with different concentrations of
recombinant human PCI (as indicated) for 45 min at 37uC in the
absence or presence of either UFH (A) or LMWH (B) at the indicated
concentrations. Remaining EP activity was quantified using Z-Lys-SBzl as
described in Materials and Methods. The activity of EP in the absence of
PCI was set as 1. Each value represents the mean of duplicates. Similar
results where obtained with different preparations of human and
mouse PCI.
doi:10.1371/journal.pone.0039262.g002
Figure 3. Determination of the apparent 2
nd order rate
constant for the inhibition of EP by PCI. EP (0.3 nM) was
incubated with indicated concentrations of recombinant human PCI
for different periods of time. Remaining enzyme activity was de-
termined as described in Materials and Methods and plotted as ln(At/
A0) versus incubation time (A). For each concentration, the negative
slope of the linear regression was calculated. This value represents the
respective pseudo 1
st order constant (k’). k’ was then replotted against
PCI concentration (B). Linear regression was used to obtain the slope of
the regression line which represents the apparent 2
nd order rate
constant (kapp). The kapp was calculated for each experiment (n=3)
separately. Each single experiment was performed in duplicates. This
yielded a kapp of 4.4860.32610
4 M
21 s
21 (mean 6 S.D., n=3). In the




6 S.D., n=3). All 3 experiments for calculating the kapp in the absence
of UFH were integrated into the figure. A: Each value represents the
mean of 3 independent experiments, each in duplicates. Error bars
show standard deviation. B: Error bars show the 95% confidence
interval of the respective k’.
doi:10.1371/journal.pone.0039262.g003
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thrombin by AT, respectively.
Western Blotting of Pancreas Lysate
Human pancreas lysate was applied to SDS-PAGE and Western
blotting. Monoclonal anti-serpinA5 IgG was used to detect PCI. A
band at about 57 kDa was seen in pancreas lysate, corresponding
to the molecular mass of PCI purified from human plasma.
Additionally, two faint bands at about 30 and 37 kDa (possible
degradation products) were seen (not shown).
Discussion
In this study, we can demonstrate that PCI is a fairly strong
inhibitor of EP, with a kapp comparable to most protease-PCI
interactions which range from 8.00610
2 M
21 s
21 for APC in-




acrosin inhibition in the presence of heparin [9,45]. It was the first
time that an interaction of EP with a serpin-type inhibitor was
shown. Additionally, it was also the first time that inhibition rate
constants and the stoichiometry of inhibition were calculated for
the interaction of a transmembrane serine protease with PCI.
It has been shown previously that heparin and phospholipids
are able to stimulate or to reduce the inhibitory activity of PCI
towards several proteases [43,46]. Glycosaminoglycans like
Figure 4. Stoichiometry of inhibition of EP by PCI. EP (0.3 nM)
was incubated overnight with varying concentrations of recombinant
human PCI in the absence and presence of 10 U/ml UFH. Remaining EP
activity was determined and plotted as relative activity against [PCI]0/
[EP]0. The x-intercept of each linear regression line represents the SI
value. The SI values were 10.860.7 without and 17.960.6 (mean 6 S.D.,
n=3) with 10 U/ml UFH, respectively. The results of one experiment are
shown in the figure. Each single experiment was done in duplicates.
doi:10.1371/journal.pone.0039262.g004
Figure 5. Bovine EP cleaves human PCI and complex formation is observed. PCI (0.05 g/l) and bovine EP (0.04 g/l) were incubated at 37uC
in a volume of 10 ml TCNB buffer for the time periods indicated. Thereafter, an equal amount of Laemmli buffer with (A) or without (B) 10% 2-
mercaptoethanol was added. For time point zero, the reagents were applied directly into Laemmli buffer. SDS-PAGE and Western blotting using
mouse anti-PCI IgG (left panel in A and B) or SDS-PAGE followed by Coomassie staining (right panel in A and B) using PageBlue solution
(Fermentas, St. Leon-Rot, Germany) were performed as described in Materials and Methods. The position of the molecular mass standard (kDa) is
indicated on the left and also visible as first lane on the right panel in A and B.
doi:10.1371/journal.pone.0039262.g005
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to the target protease as well as to the serpin [13]. In case of PCI,
this bridging mechanism is strongly protease-dependent and often
leads to enhancement of protease inhibition [47]. Interestingly, the
inhibition of plasma kallikrein by PCI is not stimulated by heparin
[3], factor Xa inhibition shows only a slight stimulation [48], and
the interaction of PCI with tissue kallikrein is completely abolished
in the presence of glycosaminoglycans [6]. Heparin slightly
reduced the inhibition of recombinant human EP by PCI and
this effect was even more pronounced using bovine EP purified
from calf intestine. This could be explained by the fact that the
recombinant EP carries a positively charged His-tag at the C-
terminus which might counteract the repulsive effect of the
negatively charged heparin.
AT, on the other hand, inhibited EP only when heparin was
present. So, heparin stimulated the inhibition of EP by AT, but
reduced the inhibition of EP by PCI. To our knowledge, this is the
first demonstration that heparin led to a reduced inhibition of
a particular protease by PCI, but an increased inhibition by AT.
This may be due to differences in regulation of serpin activity by
heparin, as AT undergoes a conformational change when bound
to glycosaminoglycans compared to the bridging mechanism of
PCI [47]. Furthermore the different heparin-binding sites of PCI
(helix H) and AT (helix D) may also contribute to this opposed
effect [14,18].
As mentioned above, native EP is a type II transmembrane
serine protease. It contains an N-terminal hydrophobic segment
from position 18 to 44, predicted to span the membrane [49,50].
The recombinant EP used is a mixture of two forms, in which the
heavy chain is truncated and starts either at Leu41 or Ser118. N-
terminal sequence analysis by Edman degradation revealed that
also the bEK contains a mixture of two heavy chains starting at
Gly53 and Ser118 respectively (personal communication:
Dr. B. Sarg, Innsbruck Medical University, Austria). Phospholi-
pids did not influence EP inhibition by PCI. Assuming a heparin-
like bridging mechanism for the stimulatory effect of phospholipids
on PCI-protease interactions, these results are not surprising, since
it has been shown previously that a truncated EP lacking the
transmembrane domain does not interact with phospholipid
vesicles [51]. Supporting this data, a commercially available
protein-lipid overlay assay containing membrane phospholipids
was performed. We could not detect any binding of recombinant
human EP to phospholipids (unpublished data). From our data it
cannot be excluded that the interaction of PCI with the
catalytically active light chain of EP is influenced by membrane
anchoring of EP. However, the huge heavy chain lies in between
the active center and the plasma membrane. This could hinder
potential phospholipid-bridging of PCI and the light chain of EP.
It is therefore not very likely that phospholipids involved in
anchoring of EP could represent a bridge for bringing together
PCI and EP.
Several publications have shown that PCI mRNA is highly
expressed in the pancreas [19,20], particularly in the exocrine part
[21]. We could show by Western blotting that PCI protein is
present in human pancreas lysate. However, we were not able to
Figure 6. Inhibition of bovine EP by PCI in the absence or
presence of UFH and phospholipid vesicles. Bovine EP (0.05 mg/
ml) was incubated with different concentrations of PCI (as indicated) for
30 min at 37uC in the absence or presence of either UFH or PAPS at the
indicated concentrations (A). In an additional activity assay for bovine
EP, PCI (10–40 nM) and UFH (0.1–100 U/ml) were added and incubated
at 37uC for 45 min. Increasing concentrations of UFH reduced the
inhibitory activity of PCI towards EP (B). Remaining EP activity was
quantified using Z-Lys-SBzl as described in Materials and Methods. The
activity of EP in the absence of PCI was set as 1. n=3 (for each figure);
error bars show standard deviation. Each single experiment was done in
duplicates.
doi:10.1371/journal.pone.0039262.g006
Figure 7. Inhibition of EP by antithrombin. EP (0.3 nM) was
incubated for 60 min at 37uC with varying concentrations of AT in the
absence and presence of UFH or LMWH (as indicated in the figure). For
comparison, inhibition by PCI (incubation time 45 min) is also included.
Remaining EP activity was quantified as described in Materials and
Methods. The activity of EP in the absence of serpins was set as 1. n=3;
error bars show standard deviation. Each single experiment was done in
duplicates.
doi:10.1371/journal.pone.0039262.g007
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on paraffin-embedded tissue sections.
Activation of trypsinogen is a crucial step in the pathogenesis of
necrotizing pancreatitis [35]. So far, it is not fully understood how
trypsinogen is activated prematurely within the pancreas. Some
authors believe that this activation might origin from reflux of EP-
containing duodenal fluid into the pancreatic duct [37]. Though,
this theory remains controversial and it is not clear if duodeno-
pancreatic reflux occurs in vivo and, if it does, whether it is really
able to damage the pancreas profoundly. However, if duodeno-
pancreatic reflux occurs under some circumstances, inhibition of
EP by PCI might have a protective effect. In addition, PCI could
protect the pancreas from autodigestion by inhibiting trypsin and
chymotrypsin [10]. Polymorphisms of PSTI (pancreatic secretory
trypsin inhibitor) are associated with a higher incidence of
pancreatitis [52], suggesting that this inhibitor may have a pro-
tective effect against this disease. Polymorphisms of PCI have been
investigated with respect to male fertility [53]. Further studies are
needed to address the question if polymorphisms of PCI might also
be associated with pancreatitis.
PCI has also been identified in the epidermis, with increasing
amounts in its more superficial layers [22,23]. Desquamation of
keratinocytes is controlled by several proteases and their inhibitors.
An imbalance between them can lead to inflammatory skin
diseases such as psoriasis [54]. Since both, EP and PCI, are
expressed in the upper epidermis [22,38], the interaction of EP
and PCI might also be involved in the regulation of epidermal
differentiation.
The SI value (10.8) of the PCI/EP-interaction is rather high,
especially in the presence of heparin (17.9), suggesting that
a significant amount of PCI is cleaved/inactivated by EP. The
biological consequences of the PCI/EP-interaction may depend
on the local [PCI]:[EP] ratio. At a high [PCI]:[EP] ratio, the
inhibition of EP would be nearly complete leading to impaired
activation of trypsinogen. Additionally, some active PCI would still
be available to inhibit trypsin directly, further reducing its activity.
At a low [PCI]:[EP] ratio, the available PCI would not be
sufficient to completely inhibit EP. Remaining active EP would
still be able to activate trypsinogen and to cleave PCI.
For the digestive system, this could mean that in the pancreatic
duct, any possibly present EP could be efficiently inhibited by PCI.
In the duodenum, where EP is abundantly present, PCI would
have only a minor effect on EP activity and would not significantly
interfere with the activation of digestive proteases.
In the epidermis, where EP is mainly localized in the superficial
layers [38], any EP present in more basal layers would be
efficiently inhibited by excess PCI. In more superficial layers, EP
would be able to activate trypsinogen in significant amounts, so it
can contribute to the desquamation process.
Materials and Methods
Materials
Expression in Escherichia coli and purification of recombinant
human and mouse PCI was performed as described previously
[55]. Citrated normal human plasma was obtained from the
Austrian Red Cross and PCI was purified as described [43].
Recombinant human EP and monoclonal mouse anti-serpinA5
IgG were obtained from R&D Systems (Minneapolis, MN). EP
purified from calf intestine was from Roche (Basel, Switzerland).
Purified human plasma AT and A1AT, thermolysin, 1,10-
phenantroline, Ellman’s reagent, purified porcine EP and dry
milk were from Sigma-Aldrich (St. Louis, MO). Z-Lys-SBzl was
from Bachem (Bubendorf, Switzerland). LMWH was from Santa
Cruz Biotechnology (Santa Cruz, CA). PAPS was from Avanti
Polar Lipids (Alabaster, AL). UFH was from Baxter (Vienna,
Austria). PVDF membranes were from Millipore (Billerica, MA).
SuperSignal West Femto was from Thermo Scientific (Rockford,
IL). Monoclonal anti-PRSS7 IgG was from Abgent (San Diego,
CA). Rabbit anti-EP-light-chain IgG was a kind gift from the lab of
J.E. Sadler (Washington University School of Medicine, St. Louis,
MO). HRP-conjugated donkey anti-rabbit and sheep anti-mouse
IgG were from GE Healthcare (Waukesha, WI). Human pancreas
lysate was from Zyagen (San Diego, CA).
Preparation of Phospholipid Vesicles
Phospholipid vesicles were prepared freshly for each experiment
as described previously [43]. In brief PAPS was dissolved in
chloroform (10 g/l) and stored at 280uC. Different aliquots of
PAPS solution were pipetted into Eppendorf tubes and chloroform
was evaporated using argon. Prewarmed buffer (37uC) was used to
resuspend dried PAPS by vortexing at maximal speed for 60
seconds followed by shaking (1400 rpm) for 5 minutes at 37uC.
Activity Assay for EP
Recombinant human EP (100 mg/ml) was activated by in-
cubation with thermolysin (3.16 mg/ml) in TCNB buffer
(50 mM Tris, 0.15 M NaCl, 10 mM CaCl2, and 0.05% Brij-35,
pH 7.5). After 30 min, the reaction was stopped by adding 10 mM
1,10-phenantroline.
To determine EP activity, Z-Lys-SBzl was used at 200 mMi n
TCNB containing 200 mM Ellman’s reagent (5,59-dithiobis-(2-
nitrobenzoic acid)). The absorption was recorded at 405 nm for
5 min to assess the activity of EP. The final concentration of
human EP was 0.3 nM in all assays. To study the inhibition of EP
by PCI and other serpins, EP was incubated with different
concentrations of the respective serpin for different periods of time
(5 to 60 min) at 37uC in a total volume of 100 ml TCNB buffer. In
some reactions, UFH (0.1–100 U/ml), LMWH (0.5–20 mg/ml), or
PAPS (100 mM) were included. The reactions were stopped by the
addition of an equal amount of substrate solution. The specific
activity of EP was 32.162.8 nmol/mg/min (mean 6 S.D., n=6).
Apparent 2
nd order rate constants for the inhibition of EP were
determined as described previously for the inhibition of other
target enzymes by PCI [6,8]. The stoichiometry of inhibition (SI)
was determined by incubating PCI (0.28–2.21 nM) and EP
(0.3 nM) overnight at 37uC in TCNB buffer. Afterwards, an
activity assay was performed. The relative EP activity was plotted
against the [PCI]0/[EP]0 ratio. Linear regression was used to
calculate the SI value (x-intercept of the linear regression line).
Lyophilized bovine EP (bEP) was reconstituted to a concentra-
tion of 0.5 mg/ml and stored in aliquots at 280uC until further
usage. The final concentration of bEP was 0.05 mg/ml and the
activity was determined as described for human EP. 1,10-
phenanthroline (used to stop the activation of human recombinant
EP) had no effect on the inhibition of bovine EP by PCI (data not
shown).
SDS-PAGE and Western Blotting
SDS-PAGE was performed according to the method of
Laemmli [56] using 10% acrylamide gels. EP (60 nM) and PCI
(440 nM) were preincubated in 10 ml TCNB buffer for varying
times at 37uC. The reactions were stopped by the addition of an
equal volume of Laemmli buffer (125 mM Tris, 20% glycerol,
4.1% SDS, 0.01% bromphenol blue with or without 10% 2-
mercaptoethanol) and heating the samples for 5 min at 95uC. For
the zero-time point the proteins were added directly into Laemmli
buffer. Thereafter, they were applied to a 10% acrylamide gel.
Protein C Inhibitor Interacts with Enteropeptidase
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membranes for Western blotting. Blocking of membranes was
done with 5% dry milk in PBST (135 nM NaCl, 1.3 mM KCl,
2.5 mM Na2HPO4, 0.5 mM KH2PO4, 0.1% Tween-20) either at
4uC overnight or at room temperature for 1 h. Incubations with
the primary antibody were also done in 5% milk in PBST at 4uC
overnight or at room temperature for 1 h. The membranes were
washed 5 times (5 min each) in PBST. The secondary peroxidase-
labeled antibody was applied for 1 h in PBST with 5% dry milk.
After another washing step, the peroxidase reaction was detected
with SuperSignal West Femto. Primary antibodies used in Western
blotting were monoclonal mouse anti-serpinA5 IgG (0.5 mg/ml),
monoclonal anti-PRSS7 (enteropeptidase) IgG (1 mg/ml) and
polyclonal rabbit anti-EP-light-chain IgG (78 mg/ml). The re-
spective secondary antibodies were HRP-conjugated donkey anti-
rabbit IgG (0.11 mg/ml), and HRP-conjugated sheep anti-mouse
IgG (0.13 mg/ml).
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